Financial Highlights - Public Cloud ARR reached $634 million, a 17% year-over-year increase, comprising 43% of Total ARR[9] - Total ARR increased by 2% year-over-year to $1.489 billion[9] - Q2'25 Recurring Revenue was $354 million, a 4% year-over-year increase[13] - Q2'25 Total Revenue was $408 million, a 6% year-over-year decrease[13] - Q2'25 GAAP Diluted EPS was $0.09, down from $0.38 in Q2'24[13] - Q2'25 Non-GAAP Diluted EPS was $0.47, down from $0.64 in Q2'24[13] - Q2'25 Cash Flow from Operations was $43 million, consistent with Q2'24[13] - Q2'25 Free Cash Flow was $39 million, consistent with Q2'24[13] Financial Outlook - The company projects FY25 Public cloud ARR growth of 14% to 18% YoY in CC[43] - The company projects FY25 Total ARR growth of flat to 2% YoY in CC[43]

Second Quarter 2025 Performance - Non-GAAP revenue reached $370 million, a 7% increase on a constant currency basis[5] - Operating profit was $102 million, a 38% increase compared to the prior year[5] - Operating margin improved to 27.5%, a 600 basis points increase year-over-year[5] - Earnings per share grew to $1.33, a 46% increase compared to the prior year[5] Pro Forma Results (Excluding New Tariffs) - Operating profit was $104 million, a 41% increase versus prior year[5] - Operating margin was 28.0%, a 650 basis points improvement versus prior year[5] - Earnings per share was $1.36, a 49% increase versus prior year[5] Business Highlights - Consumable and Service revenue reached $338 million, an 8% increase on a constant currency basis[5] - Capital and Other revenue was $32 million, a 2% decrease on a constant currency basis[5] - The company shipped 63,100 technology boards and instruments[5] Full Year 2025 Guidance (Including New Tariffs) - Revenue is projected to be between $1,505 million and $1,535 million, an 8% to 11% increase on a constant currency basis[5] - Operating profit is expected to be between $406 million and $422 million, a 23% to 28% increase versus prior year[5] - Earnings per share is projected to be between $5.20 and $5.45, a 24% to 30% increase versus prior year[5]

Q2 2025 earnings August 5, 2025 Forward looking statements This presentation contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including but not limited to, information or predictions concerning our future financial performance, including our financial outlook for Q3 2025 and the full fiscal year 2025 under the heading "Outlook" and management's estimates under the heading "Ma ...

INVESTOR PRESENTATION AUGUST 2025 2 DISCLOSURES FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position; business strategy; the market growth for our product; our ability to meet our goals related to the market position of our product and p ...

Second Quarter 2025 Earnings Call August 5, 2025 These statements are based on management's current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company's annual report on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause ...

Financial Performance - Revenues increased by 9% YoY in Q2 2025, reaching $9.179 billion, with product sales contributing $8.771 billion[9, 105] - Non-GAAP EPS grew by 21% YoY in Q2 2025, reaching $6.02[9, 105] - The company invested $1.7 billion in research and development in Q2 2025, an increase of 18% YoY[9] - Free cash flow was $1.9 billion in Q2 2025, compared to $2.2 billion in Q2 2024[107] Product Sales Highlights - Fifteen products achieved double-digit sales growth, including Repatha, EVENITY, IMDELLTRA, BLINCYTO, TEZSPIRE, UPLIZNA, and TAVNEOS[9, 17] - Repatha sales increased by 31% YoY to $696 million, driven by a 36% increase in volume[12, 23] - EVENITY sales increased by 32% YoY to $518 million, primarily driven by volume growth[12, 23] - UPLIZNA sales increased by 91% YoY to $176 million, driven by 79% volume growth[12, 27] - TEZSPIRE sales increased by 46% YoY to $342 million, driven by volume growth[12, 32] - IMDELLTRA generated $134 million in sales, with a 65% quarter-over-quarter increase[12, 37] Pipeline Development - MariTide: Phase 3 studies are enrolling for obesity and overweight, with or without Type 2 diabetes mellitus, and for adults living with heart failure with preserved or mildly reduced ejection fraction and obesity[42] - UPLIZNA: FDA review of Phase 3 data in generalized myasthenia gravis is ongoing, with a PDUFA date of December 14, 2025[46] - TEZSPIRE: FDA review of Phase 3 data in chronic rhinosinusitis with nasal polyps is ongoing, with a PDUFA date of October 19, 2025[59] - IMDELLTRA: Reduced the risk of death by 40% and significantly extended median OS by more than five months compared to SOC chemotherapy in patients with SCLC who progressed on or after one line of platinum-based chemotherapy[71]

Financial Performance - Total revenue for Q2 2025 was $105 million, a 36% year-over-year decrease[54] - Subscription Services revenue for Q2 2025 was $90 million, a 39% year-over-year decrease[65] - Chegg Study/Pack revenue decreased 44% year-over-year[14] - Adjusted EBITDA for Q2 2025 was $23 million[56] - Free cash flow for Q2 2025 was negative $12 million, impacted by severance payments[57] - Capital expenditures for Q2 2025 were $7 million, a 60% year-over-year decrease[61] Subscribers and Retention - Global Chegg Study/Pack subscribers decreased by 48% year-over-year[14] - Global Subscription Services subscribers decreased by 40% year-over-year[14] - Chegg Study/Pack monthly retention rate globally was 79.7%[14] Strategic Initiatives - The company is exploring strategic alternatives, including being acquired, undertaking a go-private transaction, or remaining as a public standalone company[12] - The company identified an additional $17 million in cost savings for 2026[11] - The company expects total non-GAAP expense savings in 2026 to be $110-120 million[11]

August 5, 2025 2025 Second Quarter Financial Results Innovating to Transform the Lives of Patients and Their Families EPIDIOLEX® patient diagnosed with Dravet syndrome Caution Concerning Forward-Looking Statements This presentation contains forward-looking statements and financial targets, including, but not limited to, statements related to: the Company's growth prospects and future financial and operating results, including the Company's 2025 financial guidance and the Company's expectations related there ...

Second Quarter 2025 Financial Results - Total revenue reached $325.7 million, a 41% increase compared to the second quarter of 2024[32] - Royalty revenue increased by 65% to $205.6 million[32] - Net income was $165.2 million, a 77% increase year-over-year[32] - Adjusted EBITDA was $225.5 million, a 65% increase compared to the same period last year[32] - GAAP diluted EPS increased by 85% to $1.33, while Non-GAAP diluted EPS increased by 69% to $1.54[32] Full Year 2025 Guidance - Total revenue is projected to be between $1.275 billion and $1.355 billion, representing a 26-33% increase[6] - Royalty revenue is expected to be between $825 million and $860 million, a 44-51% increase[6] - Adjusted EBITDA is guided to be between $865 million and $915 million, a 37-45% increase[6] - Non-GAAP diluted EPS is projected to be between $6.00 and $6.40, a 42-51% increase[6] Share Repurchase Program - The company completed a $250 million accelerated share repurchase program[6] - A new $250 million share repurchase program was announced[6]

The third quarter and full year 2025 guidance and Zeta 2028 targets provided herein are based on Zeta's current estimates and assumptions and are not a guarantee of future performance. The guidance provided and Zeta 2028 targets are subject to significant risks and uncertainties, including the risk factors discussed in the Company's reports on file with the Securities and Exchange Commission, that could cause actual results to differ materially. There can be no assurance that the Company will achieve the re ...